News
-
-
-
-
-
-
PRESS RELEASE
Theralase(R) to Host Advisory Board Meetings at Canadian Urological Association Bladder Cancer Forum and the American Urological Association
Theralase Technologies Inc. to present latest Study II interim clinical data on Ruvidar™-based photodynamic therapy for BCG-Unresponsive NMIBC CIS at upcoming Advisory Board meetings in Toronto and San Antonio -
-
PRESS RELEASE
Dr. Michael Jewett Joins Theralase(R) to Help Complete Enrollment in the Phase II Non-Muscle Invasive Bladder Cancer Clinical Study
Theralase® Technologies Inc. announces the addition of Dr. Michael Jewett as an independent consultant to assist in completing enrollment of patients in the Phase II NMIBC CIS clinical study. Dr. Jewett's expertise will help achieve regulatory approval -
PRESS RELEASE
Theralase(R) Closes $CAN 1.2 Million Non-Brokered Private Placement
Theralase Technologies Inc. has closed a non-brokered private placement offering of units, raising approximately $CAN 1,200,000 for cancer research and development. The company plans to use the funds for clinical study, preclinical research, and general corporate purposes -
PRESS RELEASE
Theralase(R) Provides Update on Phase II Bladder Cancer Clinical Study
Theralase Technologies Inc. provides an update on its Phase II Non-Muscle Invasive Bladder Cancer clinical study, demonstrating favorable interim clinical data that exceeds the International Bladder Cancer Group's guidelines. With 63 patients treated to date, the study shows promising results, potentially leading to Break Through Designation and Accelerated Approval. The Company plans to complete enrollment and delivery of the primary Study II Treatment for all patients in 2024, with potential Health Canada and FDA approval expected by 2026 / 2027.
-
Southern Energy Corp. Announces Payment of Interest in-Kind to its 8% Convertible Unsecured Subordinated Debentures
-
APWG 2024 Cybercrime Research Conference Extends Submission Deadline to July 7
-
Product Creation Studio Partners With PatchClamp Medtech Inc. to Develop Revolutionary Dural Repair System
-
XS Financial Enters Into Definitive Agreement to Be Taken Private
-
TRU Engages Investor Relations Specialists HE Capital Markets
-
DEFENCE’S ARM-X ANTI-CANCER VACCINE INHIBITS GROWTH OF PRE-ESTABLISHED OVARIAN CANCER RESULTING IN COMPLETE RESPONSES IN TREATED ANIMALS
-
Agreement reached with iBusiness Funding to acquire Funding Circle’s US business
-
Cairn Homes Plc: Transaction in Own Shares
-
Just – Evotec Biologics selected by U.S. Department of Defense for Manufacturing Optimization Program
-
HORNBACH Group delivers strong Q1 2024/25 results increasing earnings per share y-o-y by 44% – full-year outlook confirmed unchanged
-
Signing of the share purchase agreement for the acquisition of a majority stake in Neoen by Brookfield from Impala and other shareholders and of a tender agreement between Brookfield and Bpifrance
-
Schneider Electric launches an offering of bonds convertible into new shares and/or exchangeable for existing shares (OCEANEs) due 2031 for a nominal amount of €750 million and a concurrent repurchase of its outstanding OCEANEs due 2026
-
Gimv increases its stake in TINC – Gimv and Belfius conclude agreement in principle on the sale of the shares of Belfius Insurance in TINC
-
Disclosure of Share Capital and Voting Rights Outstanding as of May 31, 2024
-
2023/2024 Third Quarter Sales